Physicians, patients, and the general public are confronted with an
acute confusional state regarding the cardiovascular safety of medicines for
arthritis. Since September 30, 2004, the day that rofecoxib was precipitously
withdrawn, there has hardly been a day without significant news on the general
topic of cyclooxygenase 2 (COX-2) inhibitors. On December 9, 2004, the US
Food and Drug Administration (FDA) issued a black box warning for valdecoxib
for life-threatening skin reactions and cardiovascular risk.1 Just
over a week later, on December 17, 2004, the National Cancer Institute announced
the premature cessation of a trial of celecoxib known as Adenoma Prevention
with Celecoxib (APC) due to a significant excess of cardiovascular death,
myocardial infarction (MI), and stroke.2
The difference for events between the 400-mg and 800-mg dose was not
significant (OR, 0.7 [95% CI, 0.4-1.4]; P =.30). OR
indicates odds ratio; CI, confidence interval. The dose response trend across
all groups, P =.007.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 78
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination EDUCATION GUIDESSeptic Arthritis
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.